KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Edwards Lifesciences (EW) Gross Margin (2016 - 2026)

Edwards Lifesciences has reported Gross Margin over the past 17 years, most recently at 78.15% for Q4 2025.

  • For Q4 2025, Gross Margin fell 77.0% year-over-year to 78.15%; the TTM value through Dec 2025 reached 78.01%, down 144.0%, while the annual FY2025 figure was 78.01%, 144.0% down from the prior year.
  • Gross Margin for Q4 2025 was 78.15% at Edwards Lifesciences, roughly flat from 77.77% in the prior quarter.
  • Over five years, Gross Margin peaked at 122.98% in Q4 2022 and troughed at 75.7% in Q2 2021.
  • A 5-year average of 80.91% and a median of 78.78% in 2025 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: surged 4626bps in 2022 and later tumbled -4280bps in 2023.
  • Year by year, Gross Margin stood at 76.72% in 2021, then skyrocketed by 60bps to 122.98% in 2022, then crashed by -35bps to 80.18% in 2023, then decreased by -2bps to 78.91% in 2024, then fell by -1bps to 78.15% in 2025.
  • Business Quant data shows Gross Margin for EW at 78.15% in Q4 2025, 77.77% in Q3 2025, and 77.52% in Q2 2025.